Heike Knüpfer1, Rainer Preiss. 1. Institute of Clinical Pharmacology, University of Leipzig, Härtelstrasse 16-18, 04107 Leipzig, Germany. Heike.Knuepfer@medizin.uni-leipzig.de
Abstract
INTRODUCTION: It is now clear that inflammation and cancer initiation and progression are linked. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine with described cancer stimulatory and also cancer inhibitory properties. The study's aim was to assess the potential of circulating IL-6 as a prognostic indicator in colorectal cancer. MATERIALS AND METHODS: A literature search was conducted using PubMed, restricted to articles published in English language. We compared published results in regard to differences in IL-6 levels between healthy controls and colon cancer patients (seven published results), between patients with increasing tumor stages (eight published results), between patients with differences in tumor size (four published results), and between patients with and without liver (three published results) or lung metastasis (one published result). Furthermore, we reviewed the literature in regard to the possible correlation of IL-6 levels with survival time (five published results) and correlation of IL-6 levels and lymph node involvement (three published results). RESULTS: Concerning colon tumors, results are consistent. Colon cancer patients reveal higher serum IL-6 levels than healthy controls. Furthermore, higher IL-6 levels are associated with increasing tumor stages and tumor size, with metastasis and decreased survival. CONCLUSION: Therefore, circulating IL-6 might be prognostic indicator in colorectal cancer.
INTRODUCTION: It is now clear that inflammation and cancer initiation and progression are linked. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine with described cancer stimulatory and also cancer inhibitory properties. The study's aim was to assess the potential of circulating IL-6 as a prognostic indicator in colorectal cancer. MATERIALS AND METHODS: A literature search was conducted using PubMed, restricted to articles published in English language. We compared published results in regard to differences in IL-6 levels between healthy controls and colon cancerpatients (seven published results), between patients with increasing tumor stages (eight published results), between patients with differences in tumor size (four published results), and between patients with and without liver (three published results) or lung metastasis (one published result). Furthermore, we reviewed the literature in regard to the possible correlation of IL-6 levels with survival time (five published results) and correlation of IL-6 levels and lymph node involvement (three published results). RESULTS: Concerning colon tumors, results are consistent. Colon cancerpatients reveal higher serum IL-6 levels than healthy controls. Furthermore, higher IL-6 levels are associated with increasing tumor stages and tumor size, with metastasis and decreased survival. CONCLUSION: Therefore, circulating IL-6 might be prognostic indicator in colorectal cancer.
Authors: Gennaro Galizia; Michele Orditura; Ciro Romano; Eva Lieto; Paolo Castellano; Luigi Pelosio; Vincenzo Imperatore; Giuseppe Catalano; Carlo Pignatelli; Ferdinando De Vita Journal: Clin Immunol Date: 2002-02 Impact factor: 3.969
Authors: C Becker; M C Fantini; S Wirtz; A Nikolaev; H A Lehr; P R Galle; S Rose-John; M F Neurath Journal: Cell Cycle Date: 2005-02-03 Impact factor: 4.534
Authors: A Tchirkov; T Khalil; E Chautard; K Mokhtari; L Véronèse; B Irthum; P Vago; J-L Kémény; P Verrelle Journal: Br J Cancer Date: 2007-01-16 Impact factor: 7.640
Authors: Jamie L McClellan; J Mark Davis; Jennifer L Steiner; Stani D Day; Susan E Steck; Martin D Carmichael; E Angela Murphy Journal: Cytokine Date: 2011-11-04 Impact factor: 3.861
Authors: Lei Wang; Andrea K Miyahira; Diana L Simons; Xuyang Lu; Andrew Y Chang; Carrie Wang; Maria A Suni; Vernon C Maino; Frederick M Dirbas; John Yim; James Waisman; Peter P Lee Journal: Cancer Res Date: 2016-11-22 Impact factor: 12.701
Authors: Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti Journal: J Pharmacol Exp Ther Date: 2014-05-09 Impact factor: 4.030
Authors: Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke Journal: Crit Rev Immunol Date: 2013 Impact factor: 2.214